---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017382"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:57:56.963905+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium Q2 net loss $14.1M (-$0.41/sh); cash $57.6M; clinical pipeline on track

## Summary
- Net loss $14.1M, or $(0.41) per share, vs $9.2M ($0.31) in Q2 2021; R&D spend $9.5M.
- Cash, cash equivalents and short-term investments $57.6M as of June 30, 2022.
- Phase 3 EQUATOR study of itolizumab in aGVHD continues enrollment; interim data from lupus nephritis study expected mid-2022.
- Phase 2 study of EQ101 in alopecia areata and Phase 1 study of EQ102 in celiac disease expected to initiate 2H 2022.

## SEC filing metadata
- accession: 0000950170-22-017382
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/0000950170-22-017382-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017022017382/eq-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017382
- JSON: https://secwatch.observer/filing/0000950170-22-017382.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017382.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.